TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7869865

Group type: EXPERIMENTAL
Intervention: Conservative management; details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery; details on dosage and duration not specified.
Number of subjects: 0
Study: 2073672

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg q.p.m. (doubled if LDL > 140 mg/dl after 6 weeks)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Fenofibrate 200 mg b.i.d.
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 184
Study: 6459256

Group type: EXPERIMENTAL
Intervention: Tizanidine (5-Chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole), administered t.i.d. for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diazepam, administered t.i.d. for 7 days
Number of subjects: 20
Study: 31870334

Group type: EXPERIMENTAL
Intervention: Village-based intervention (Pneumonia Awareness Sessions conducted by community health workers)
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Facility-based intervention (Pneumonia Awareness Sessions conducted by community health workers)
Number of subjects: 812
Study: 29067761

Group type: EXPERIMENTAL
Intervention: Therapies that improve outcomes in heart failure with reduced ejection fraction (HFrEF)
Number of subjects: 0
Study: 25733635

Group type: EXPERIMENTAL
Intervention: High-flavanone (305 mg) 100% orange juice
Number of subjects: 37

Group type: COMPARATOR
Intervention: Low-flavanone (37 mg) orange-flavored cordial (500 mL)
Number of subjects: 37
Study: 25122819

Group type: EXPERIMENTAL
Intervention: Individualized CRC risk information (prepared by a research assistant)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard CRC screening handout
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Individualized CRC risk information
Number of subjects: 210
Study: 23032168

Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY-tetanus toxoid conjugate vaccine (ACWY-TT group; n = 231)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Licensed meningococcal ACWY polysaccharide vaccine (Men-PS group; n = 78)
Number of subjects: 309
Study: 18435692

Group type: EXPERIMENTAL
Intervention: Psychological characteristics assessed by a self-administered questionnaire
Number of subjects: 1430
Study: 17148749

Group type: EXPERIMENTAL
Intervention: PYY(3‐36) (0.8 pmol x kg(‐1) x min(‐1))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PYY(3‐36) (0.2 pmol x kg(‐1) x min(‐1))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PYY(1‐36) (1.6 pmol x kg(‐1) x min(‐1))
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study: 16194338

Group type: EXPERIMENTAL
Intervention: Adjustable oblique position
Number of subjects: 128

Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 128
Study: 12381039

Group type: EXPERIMENTAL
Intervention: Virtual-reality (VR) treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cognitive-behavioral psychonutritional groups (Control)
Number of subjects: 20
Study: 10541760

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day) plus calcium (1000 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alendronate in high turnover (HT) patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alendronate in low turnover (LT) patients
Number of subjects: 100
Study: 7762531

Group type: EXPERIMENTAL
Intervention: Arabica coffee oil (2 g daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Robusta coffee oil (2 g daily)
Number of subjects: 36
Study: 2191751

Group type: COMPARATOR
Intervention: Prepacol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Whole gut irrigation
Number of subjects: 100
Study: 277749

Group type: EXPERIMENTAL
Intervention: DAT (Daunomycin, cytosine arabinoside, and 6-thioguanine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: VAT (Vincristine, cytosine arabinoside, and 6-thioguanine)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DAT
Number of subjects: 100

Group type: COMPARATOR
Intervention: VAT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both DAT and VAT
Number of subjects: 100
Study: 29498061

Group type: EXPERIMENTAL
Intervention: Nutritionally optimized default menu
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard menu (suboptimal default)
Number of subjects: 127
Study: 27430755

Group type: EXPERIMENTAL
Intervention: Ancient peat and apple extract (TRT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 25
Study: 25421252

Group type: EXPERIMENTAL
Intervention: Capecitabine alone (500-825 mg/m2/bid, days 1-21)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Capecitabine plus Valproic acid (oral daily, day -14 to 21, target serum level 50-100 microg/ml)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Short-course radiotherapy (SCRT) (5 fractions of 5 Gy, days 1-5)
Number of subjects: 86
Study: 22905926

Group type: EXPERIMENTAL
Intervention: Kidney disease (KD)
Number of subjects: 2642

Group type: EXPERIMENTAL
Intervention: Renal impairment (RI)
Number of subjects: 2642

Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 2642

Group type: EXPERIMENTAL
Intervention: Diabetic nephropathy (DN)
Number of subjects: 2642

Group type: EXPERIMENTAL
Intervention: Albuminuria without RI
Number of subjects: 2642

Group type: EXPERIMENTAL
Intervention: Nonalbuminuric RI
Number of subjects: 2642
Study: 20484058

Group type: EXPERIMENTAL
Intervention: Culturally relevant group diabetes self‐management training (DSMT), coping skills training (CST), and diabetes care intervention
Number of subjects: 109

Group type: COMPARATOR
Intervention: Usual diabetes education and diabetes care intervention
Number of subjects: 109
Study: 18029924

Group type: EXPERIMENTAL
Intervention: Breath holding at inspiration
Number of subjects: 23

Group type: COMPARATOR
Intervention: Free breathing
Number of subjects: 23

Group type: COMPARATOR
Intervention: Breath holding at expiration
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Healthy subjects during breath holding at inspiration
Number of subjects: 23
Study: 15809933

Group type: EXPERIMENTAL
Intervention: TARGeted Intraoperative radiotherapy (TARGIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional postoperative radiotherapy
Number of subjects: 0
Study: 12383160

Group type: EXPERIMENTAL
Intervention: Specialized heart failure disease-management programs
Number of subjects: 1937

Group type: EXPERIMENTAL
Intervention: Specialized follow-up by multidisciplinary teams
Number of subjects: 1937

Group type: COMPARATOR
Intervention: Follow-up by primary care physicians and telephone
Number of subjects: 1937

Group type: EXPERIMENTAL
Intervention: Specialized disease-management programs
Number of subjects: 1937

Group type: EXPERIMENTAL
Intervention: Quality of life or functional status
Number of subjects: 1937

Group type: EXPERIMENTAL
Intervention: Cost analyses
Number of subjects: 1937
Study: 10447991

Group type: EXPERIMENTAL
Intervention: Presence of emphasis in narratives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low linguistic complexity condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High linguistic complexity condition
Number of subjects: 0
Study: 7598669

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 10-session treatment package including progressive relaxation, rational thinking, and pain coping strategies.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 3
Study: 2358617

Group type: EXPERIMENTAL
Intervention: 15 mg Zn daily for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg Zn daily for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 475632

Group type: EXPERIMENTAL
Intervention: Isotonic saline drops every three hours for one week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic saline drops
Number of subjects: 20

Group type: COMPARATOR
Intervention: One-half isotonic saline solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tear film osmolarity
Number of subjects: 20
Study: 30944054

Group type: EXPERIMENTAL
Intervention: Smartphone-based monitoring
Number of subjects: 129

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 129
Study: 31128251

Group type: EXPERIMENTAL
Intervention: Post-operative (1 month after operation)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Post-operative (2 months after operation)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Post-operative (3 months after operation)
Number of subjects: 9
Study: 28616923

Group type: EXPERIMENTAL
Intervention: Tramadol 0.5 mg/kg (TRM1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg/kg (TRM2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tramadol 1.5 mg/kg (TRM3)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (Control group)
Number of subjects: 120
Study: 25825006

Group type: EXPERIMENTAL
Intervention: Web-based monthly monitoring with the Childhood Asthma Control Test (ACT)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: 4-monthly monitoring of FENO
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Web-based ACT monitoring
Number of subjects: 280
Study: 24068825

Group type: EXPERIMENTAL
Intervention: Quetiapine 150 mg XL for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21586690

Group type: EXPERIMENTAL
Intervention: GLP‐1(7‐36) amide at 1.2 pmol/kg per minute
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study: 19447598

Group type: EXPERIMENTAL
Intervention: Single-shot spinal
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combined spinal-epidural
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural volume extension of a combined spinal-epidural
Number of subjects: 60
Study: 16597716

Group type: EXPERIMENTAL
Intervention: fMRI response to local contrast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modulating a surrounding field
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modeling fMRI responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurons identified in neurophysiological studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual field maps of human V1 and V2
Number of subjects: 0
Study: 12699266

Group type: EXPERIMENTAL
Intervention: Surgical ablation or resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation techniques with intrauterine inseminations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVF (In Vitro Fertilization)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pretreatment with GnRH agonists before IVF cycle initiation
Number of subjects: 0
Study: 11092289

Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg before meals
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg three times a day
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Combination therapy (nateglinide + metformin)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study: 9170525

Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of 5 mg azasetron before and 8 hours after chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard group receiving intravenous bolus injection of 10 mg azasetron once a day
Number of subjects: 0
Study: 15374310

Group type: EXPERIMENTAL
Intervention: Single visit from health visitor at 72 hours
Number of subjects: 204

Group type: COMPARATOR
Intervention: Normal follow-up services (Control)
Number of subjects: 204
Study: 2971310

Group type: EXPERIMENTAL
Intervention: Celiprolol (400 mg once a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30313092

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) (propofol and remifentanil)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Desflurane anesthesia (DES) (desflurane and remifentanil)
Number of subjects: 56
Study: 25913923

Group type: EXPERIMENTAL
Intervention: IR/ER HB/APAP (7.5/325 mg) fixed-dose combination analgesic agent, initial dose of 22.5/975 mg on day 1, followed by 15/650 mg every 12 hours for up to 35 days.
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: IR/ER HB/APAP (7.5/325 mg) fixed-dose combination analgesic agent.
Number of subjects: 153
Study: 24469870

Group type: EXPERIMENTAL
Intervention: N-3 polyunsaturated fatty acids (Omacor) 1 g daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard therapy + 75 mg acetylsalicylic acid + 75 mg clopidogrel)
Number of subjects: 40
Study: 20861530

Group type: EXPERIMENTAL
Intervention: Energicer (COOL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 18
Study: 19048591

Group type: EXPERIMENTAL
Intervention: Corticosteroids alone
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Corticosteroids and azathioprine
Number of subjects: 253

Group type: COMPARATOR
Intervention: ACE inhibitors alone or associated with corticosteroids
Number of subjects: 253
Study: 15857350

Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 12643610

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 21
Study: 10917259

Group type: EXPERIMENTAL
Intervention: Molded ankle-foot orthosis (MAFO)
Number of subjects: 4
Study: 8945863

Group type: EXPERIMENTAL
Intervention: Stepwise linear discriminant analysis applied to electromyographic interference patterns
Number of subjects: 186
Study: 1959498

Group type: EXPERIMENTAL
Intervention: Tetrabamate (900 mg/day)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Lorazepam (4.5 mg/day)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Tetrabamate
Number of subjects: 269
Study: 6753119

Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg/daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31419809

Group type: EXPERIMENTAL
Intervention: Combined resistance training with sport-specific drill (CRT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Resistance training without any sport-specific drill training (NSDT)
Number of subjects: 22
Study: 28713109

Group type: EXPERIMENTAL
Intervention: 2% neem mouthwash
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate
Number of subjects: 40
Study: 25855267

Group type: EXPERIMENTAL
Intervention: Extended-release carbidopa-levodopa (ER CD-LD) 97.5 mg-390 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release carbidopa-levodopa (IR CD-LD) 25 mg-100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sustained-release carbidopa-levodopa (CR CD-LD) 25 mg-100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbidopa-levodopa-entacapone (Stalevo) 25 mg-100 mg-200 mg
Number of subjects: 0
Study: 23942038

Group type: EXPERIMENTAL
Intervention: Double dose of levocetirizine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional dose of levocetirizine
Number of subjects: 0
Study: 21286837

Group type: EXPERIMENTAL
Intervention: Revised consent laws for HIV testing
Number of subjects: 53036383

Group type: EXPERIMENTAL
Intervention: Increased diagnosis rate (24.8-72.3%)
Number of subjects: 53036383

Group type: EXPERIMENTAL
Intervention: Proportion of HIV-infected persons refusing testing exceeds 18.2%
Number of subjects: 53036383
Study: 19675538

Group type: EXPERIMENTAL
Intervention: Catecholamine depletion (CD) achieved by oral administration of alpha‐methyl‐paratyrosine (AMPT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy female controls
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Affective Stroop task
Number of subjects: 27
Study: 17877165

Group type: EXPERIMENTAL
Intervention: Group A + C meningococcal polysaccharide vaccine (100 microg)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Group A meningococcal polysaccharide vaccine (50 microg)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Typhoid Vi polysaccharide vaccine (30 microg)
Number of subjects: 428
Study: 15190797

Group type: EXPERIMENTAL
Intervention: PDLLA biomembrane
Number of subjects: 68

Group type: COMPARATOR
Intervention: Traditional surgical method
Number of subjects: 68
Study: 11550752

Group type: EXPERIMENTAL
Intervention: Delay making the decision (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memorize the case (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehend the case (Experiment 3)
Number of subjects: 0
Study: 9778712

Group type: EXPERIMENTAL
Intervention: 2.5% hydroxyethyl starch
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3% gelatin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 4% human albumin
Number of subjects: 36
Study: 8012622

Group type: EXPERIMENTAL
Intervention: Formal training in smoking cessation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intervention with smokers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Smoke-free policies
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Printed materials on smoking cessation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Staff coordination for smoking cessation activities
Number of subjects: 30
Study: 2902263

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) measles vaccine, 40,000 plaque forming units
Number of subjects: 558

Group type: COMPARATOR
Intervention: Schwarz measles vaccine, 6000 tissue culture infectious units
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) measles vaccine
Number of subjects: 558
Study: 31204129

Group type: EXPERIMENTAL
Intervention: Single-dose Custodiol histidine‐tryptophan‐ketoglutarate
Number of subjects: 110

Group type: COMPARATOR
Intervention: Repetitive cold‐blood cardioplegia
Number of subjects: 110
Study: 31634179

Group type: EXPERIMENTAL
Intervention: Near-total thyroidectomy (NTT)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Total thyroidectomy (TT)
Number of subjects: 205
Study: 28256384

Group type: EXPERIMENTAL
Intervention: Headless, cannulated Herbert screws
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional locking plate system
Number of subjects: 40
Study: 25421802

Group type: EXPERIMENTAL
Intervention: High-fidelity patient simulation (HFPS)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no HFPS)
Number of subjects: 55
Study: 23586936

Group type: EXPERIMENTAL
Intervention: Lawsone methyl ether (LME) mouthwash
Number of subjects: 67

Group type: COMPARATOR
Intervention: Chlorhexidine (CHX) mouthwash
Number of subjects: 67
Study: 21592508

Group type: EXPERIMENTAL
Intervention: Zinc plus placebo vitamin A (group 1)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Zinc plus other micronutrients plus vitamin A (group 2)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Zinc plus vitamin A (group 3)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo (group 4)
Number of subjects: 167
Study: 18665763

Group type: EXPERIMENTAL
Intervention: Er:YAG laser, 250 mJ, at 2 Hz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Er:YAG laser, 250 mJ, at 3 Hz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Er:YAG laser, 250 mJ, at 4 Hz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Er:YAG laser, 350 mJ, at 2 Hz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Er:YAG laser, 350 mJ, at 3 Hz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Er:YAG laser, 350 mJ, at 4 Hz
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-speed handpiece (control)
Number of subjects: 12
Study: 16446183

Group type: EXPERIMENTAL
Intervention: Fondaparinux administered 8 +/- 2 hours after surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fondaparinux administered the morning after surgery
Number of subjects: 0
Study: 12946548

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg BID via single-dose dry powder inhaler plus on‐demand salbutamol
Number of subjects: 6155

Group type: EXPERIMENTAL
Intervention: Formoterol plus on‐demand salbutamol
Number of subjects: 6155

Group type: COMPARATOR
Intervention: On-demand salbutamol alone or salmeterol 50 microg BID via multidose dry powder inhaler plus on‐demand salbutamol
Number of subjects: 6155
Study: 11194599

Group type: EXPERIMENTAL
Intervention: 5 mmol intravenous magnesium
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 10 mmol intravenous magnesium
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20 mmol intravenous magnesium
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0 mmol intravenous magnesium (placebo)
Number of subjects: 36
Study: 9375333

Group type: EXPERIMENTAL
Intervention: 100% O2
Number of subjects: 34

Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 34
Study: 1488561

Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 micrograms salbutamol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2999455

Group type: EXPERIMENTAL
Intervention: Low-dose oral acyclovir
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 40
Study: 31628723

Group type: EXPERIMENTAL
Intervention: Online automated pain coping skills training program (PCST) for 8 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Online automated pain coping skills training program (PCST)
Number of subjects: 12
Study: 29658344

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metformin (M) + Oral contraceptives (OCP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Metformin (M)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pooled data (M, OCP, M + OCP)
Number of subjects: 90
Study: 27982406

Group type: EXPERIMENTAL
Intervention: Phytotherapy (Gan Mai Da Zao formula, 50 ml)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 24572995

Group type: EXPERIMENTAL
Intervention: Prilocaine-lidocaine (PLA) cream applied to the glans penis for 10 min before measurements
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo cream applied to the glans penis for 10 min before measurements
Number of subjects: 60
Study: 22498045

Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine (routine intravenous narcotics)
Number of subjects: 40